A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients-Reference-Cited by-同舟云学术

A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients

Published:2022-05 Issue: Volume:128 Page:105860
ISSN:1368-8375
Container-title:Oral Oncology
language:en
Short-container-title:Oral Oncology

Author:

Chen Yu,Zheng Xiaobin,Lin Jing,Gao Xuan,Xiong Jiani,Liu Jun,Fei Zhaodong,Chen Chuanben

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Oral Surgery

Reference61 articles.

1. Cancer Statistics, 2021;Siegel;CA Cancer J Clin,2021

2. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis;Pulte;Oncologist,2010

3. The DNA damage response and cancer therapy;Lord;Nature,2012

4. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer;Konstantinopoulos;Cancer Discovery,2015

5. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action;Pommier;Sci Transl Med,2016

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Homologous recombination deficiency (HRD) is associated with better prognosis and possibly causes a non‐inflamed tumour microenvironment in nasopharyngeal carcinoma;The Journal of Pathology: Clinical Research;2024-08-05

2. Multiomics analysis of homologous recombination deficiency across cancer types;Biomolecules and Biomedicine;2024-07-28

3. A Review of the Repair of DNA Double Strand Breaks in the Development of Oral Cancer;International Journal of Molecular Sciences;2024-04-07

4. Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, phase II clinical trial;Frontiers in Immunology;2024-02-01

5. Homologous recombination deficiency reflects the heterogeneity and monitoring treatment response for patients with breast cancer;The Journal of Gene Medicine;2023-11-23